These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 20306004)
1. Study design considerations: conducting global clinical trials in early Alzheimer's disease. Schindler RJ J Nutr Health Aging; 2010 Apr; 14(4):312-4. PubMed ID: 20306004 [TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073 [TBL] [Abstract][Full Text] [Related]
4. The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. Schneider LS J Nutr Health Aging; 2010 Apr; 14(4):295-8. PubMed ID: 20305999 [TBL] [Abstract][Full Text] [Related]
5. Scales as outcome measures for Alzheimer's disease. Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103 [TBL] [Abstract][Full Text] [Related]
6. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Mani RB Stat Med; 2004 Jan; 23(2):305-14. PubMed ID: 14716731 [TBL] [Abstract][Full Text] [Related]
7. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914 [TBL] [Abstract][Full Text] [Related]
8. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease. Fillit H; Cummings J; Neumann P; McLaughlin T; Salavtore P; Leibman C J Nutr Health Aging; 2010 Oct; 14(8):640-7. PubMed ID: 20922340 [TBL] [Abstract][Full Text] [Related]
9. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial. Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M Trials; 2018 May; 19(1):291. PubMed ID: 29793540 [TBL] [Abstract][Full Text] [Related]
10. Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design. Doody RS J Nutr Health Aging; 2010 Apr; 14(4):299-302. PubMed ID: 20306000 [TBL] [Abstract][Full Text] [Related]
11. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development. Morant AV; Vestergaard HT; Lassen AB; Navikas V Clin Transl Sci; 2020 Jul; 13(4):652-664. PubMed ID: 32043310 [TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
13. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420 [TBL] [Abstract][Full Text] [Related]
14. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879 [TBL] [Abstract][Full Text] [Related]
15. The future is now: model-based clinical trial design for Alzheimer's disease. Romero K; Ito K; Rogers JA; Polhamus D; Qiu R; Stephenson D; Mohs R; Lalonde R; Sinha V; Wang Y; Brown D; Isaac M; Vamvakas S; Hemmings R; Pani L; Bain LJ; Corrigan B; ; Clin Pharmacol Ther; 2015 Mar; 97(3):210-4. PubMed ID: 25669145 [TBL] [Abstract][Full Text] [Related]
17. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States. Tsukamoto K Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940 [TBL] [Abstract][Full Text] [Related]
18. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Hampel H; Lista S; Khachaturian ZS Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Arnerić SP; Batrla-Utermann R; Beckett L; Bittner T; Blennow K; Carter L; Dean R; Engelborghs S; Genius J; Gordon MF; Hitchcock J; Kaplow J; Luthman J; Meibach R; Raunig D; Romero K; Samtani MN; Savage M; Shaw L; Stephenson D; Umek RM; Vanderstichele H; Willis B; Yule S J Alzheimers Dis; 2017; 55(1):19-35. PubMed ID: 27662307 [TBL] [Abstract][Full Text] [Related]